JohannaChockBendellMD

Clinical Trials

• Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer Start of enrollment: 2009 Mar 01

  Completed

  Phase 2

• Study of Perifosine + Capecitabine for Colon Cancer Patients Start of enrollment: 2009 Oct 01

  Completed

  Phase 1

• Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer Start of enrollment: 2010 Apr 01

  Completed

  Phase 3

• Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Start of enrollment: 2010 May 01

  Completed

  Phase 2

• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01

  Active, not recruiting

  Phase 3

• Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer Start of enrollment: 2010 Jul 01

  Completed

  Phase 1

• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Start of enrollment: 2010 Jul 20

  Completed

  Phase 1, Phase 2

• FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only Start of enrollment: 2010 Dec 01

  Completed

  Phase 2

• A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors Start of enrollment: 2010 Nov 01

  Completed

  Phase 1

• E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Jul 19

  Completed

  Phase 1, Phase 2

• E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2011 Sep 19

  Completed

  Phase 1, Phase 2

• Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors Start of enrollment: 2011 Apr 01

  Completed

  Phase 1

• A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01

  Completed

  Phase 1, Phase 2

• Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23

  Completed

  Phase 2

• Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC Start of enrollment: 2013 Jun 19

  Completed

  Phase 1

• Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer Start of enrollment: 2013 Feb 01

  Terminated

  Phase 2

• Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29

  Completed

  Phase 1

• A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab Start of enrollment: 2014 May 05

  Completed

  Phase 1

• ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors Start of enrollment: 2014 Apr 01

  Terminated

  Phase 1, Phase 2

• Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases Start of enrollment: 2014 Jul 01

  Completed

  Phase 2

• A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Start of enrollment: 2015 Apr 29

  Completed

  Phase 2

• A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Start of enrollment: 2015 Jul 29

  Completed

  Phase 1

• A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Start of enrollment: 2015 Jul 16

  Completed

  Phase 1

• A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Start of enrollment: 2015 Nov 06

  Completed

  Phase 1

• Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Start of enrollment: 2015 Dec 28

  Completed

  Phase 3

• A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Start of enrollment: 2016 May 19

  Active, not recruiting

  Phase 2

• A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer Start of enrollment: 2016 Jun 15

  Completed

  Phase 1

• Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Start of enrollment: 2017 Jul 28

  Terminated

  Phase 2

• A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Start of enrollment: 2017 Jan 12

  Completed

  Phase 2

• A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Start of enrollment: 2017 Jun 22

  Completed

  Phase 1, Phase 2

• PRS-343 in HER2-Positive Solid Tumors Start of enrollment: 2017 Sep 13

  Completed

  Phase 1

• MGD009/MGA012 Combination in Relapsed/Refractory Cancer Start of enrollment: 2018 Feb 27

  Completed

  Phase 1

• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Start of enrollment: 2018 May 02

  Recruiting

  Phase 1, Phase 2

• A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Start of enrollment: 2018 Dec 19

  Completed

  Phase 1

• A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread Start of enrollment: 2019 Dec 23

  Completed

  Phase 1

• Join now to see all